Isis Enterprise shares best practice with Latin American innovators
45 innovators from Mexico, Brazil, and Chile spent two weeks in London in December, learning the business of innovation from Isis Enterprise (IE).
We publish news of technology innovations, investment opportunities, together with updates from spinout & startup companies and licensees
45 innovators from Mexico, Brazil, and Chile spent two weeks in London in December, learning the business of innovation from Isis Enterprise (IE).
Celleron Therapeutics is developing personalised medicine for cancer patients. The company has announced results from its first human trial in patients at Oxford’s Churchill Hospital with advanced treatment-resistant aggressive cancer.
Nasdaq-listed Oxford spinout Summit Therapeutics has hit its first research milestone as part of a multiyear strategic alliance with the University of Oxford. The collaboration is focussed on developing future-generation utrophin modulators for the potential treatment of all patients with the progressive muscle wasting disorder Duchenne Muscular Dystrophy.
Summit Therapeutics and Oxford have announced a multi-year extension of their strategic alliance for the development of utrophin modulators to treat Duchenne Muscular Dystrophy.
iOutcomes will be represented at the IDF World Diabetes Congress to be held in Vancouver, from November 30th - December 4th 2015.
Perspectum announced today it has been given US FDA clearance to market its test for diagnosing and measuring liver disease.
Oxford University Innovation spinout OrganOx has received CE mark certification for its OrganOx metra device, which improves the success of liver transplantation.
Outside London, it is arguable that no other region has had more of an effect on the evolution of the UK than Oxford. From custodians of the English language to leaders of the country, Oxford has continued to have a major impact on the shape and destiny of the British people.